Bevacizumab Given With Either Anastrozole or Fulvestrant With Trastuzumab for Postmenopausal Metastatic Breast Cancer
Status:
Completed
Trial end date:
2011-06-01
Target enrollment:
Participant gender:
Summary
This is a phase II trial combining bevacizumab with either fulvestrant or anastrozole with
trastuzumab in the treatment of metastatic breast cancer in postmenopausal women. It is hoped
that these combinations will keep the cancer from growing and spreading further.